Mizuho Issues Pessimistic Forecast for Teleflex (NYSE:TFX) Stock Price

Teleflex (NYSE:TFX) had its price objective reduced by equities researchers at Mizuho from $275.00 to $250.00 in a report released on Friday, Benzinga reports. The firm currently has a “neutral” rating on the medical technology company’s stock. Mizuho’s price objective suggests a potential upside of 18.37% from the stock’s previous close.

Several other brokerages also recently commented on TFX. Stephens increased their price objective on shares of Teleflex from $275.00 to $290.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Royal Bank of Canada raised their price objective on Teleflex from $260.00 to $275.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Truist Financial upped their target price on Teleflex from $247.00 to $255.00 and gave the stock a “hold” rating in a report on Monday, October 14th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Teleflex in a research note on Friday. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $262.75.

Teleflex Trading Up 5.0 %

Shares of TFX stock opened at $211.21 on Friday. Teleflex has a fifty-two week low of $190.49 and a fifty-two week high of $257.85. The stock’s fifty day moving average price is $239.55 and its two-hundred day moving average price is $224.02. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.44 and a current ratio of 2.42. The company has a market cap of $9.95 billion, a PE ratio of 41.99, a P/E/G ratio of 1.82 and a beta of 1.18.

Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, October 31st. The medical technology company reported $3.49 earnings per share for the quarter, beating the consensus estimate of $3.38 by $0.11. The business had revenue of $764.40 million for the quarter, compared to analyst estimates of $768.68 million. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. Teleflex’s revenue was up 2.4% compared to the same quarter last year. During the same period last year, the firm posted $3.64 earnings per share. Equities analysts predict that Teleflex will post 13.97 EPS for the current fiscal year.

Insider Buying and Selling at Teleflex

In other news, Director Stuart A. Randle sold 2,674 shares of the company’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $238.93, for a total value of $638,898.82. Following the sale, the director now directly owns 5,496 shares of the company’s stock, valued at approximately $1,313,159.28. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 1.43% of the company’s stock.

Hedge Funds Weigh In On Teleflex

Several hedge funds and other institutional investors have recently bought and sold shares of TFX. Verdence Capital Advisors LLC raised its position in shares of Teleflex by 6.4% in the 3rd quarter. Verdence Capital Advisors LLC now owns 1,622 shares of the medical technology company’s stock worth $401,000 after acquiring an additional 97 shares in the last quarter. Capital Performance Advisors LLP acquired a new position in Teleflex in the third quarter valued at approximately $54,000. Principal Financial Group Inc. boosted its holdings in shares of Teleflex by 2.7% during the 3rd quarter. Principal Financial Group Inc. now owns 80,409 shares of the medical technology company’s stock worth $19,887,000 after buying an additional 2,086 shares in the last quarter. Sentry Investment Management LLC acquired a new stake in shares of Teleflex during the 3rd quarter worth approximately $59,000. Finally, QRG Capital Management Inc. acquired a new stake in shares of Teleflex during the 3rd quarter worth approximately $509,000. Institutional investors and hedge funds own 95.62% of the company’s stock.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.